Piperazine sulfonamides as potent, selective, and orally available 11β-hydroxysteroid dehydrogenase type 1 inhibitors with efficacy in the rat cortisone-induced hyperinsulinemia model

Journal of Medicinal Chemistry

Volumn 51, Issue 14, 2008, Pages 4068-4071

  Xiang, Jason ^a   Wan, Zhao Kui ^a   Li, Huan Qiu ^a   Ipek, Manus ^a   Binnun, Eva ^a   Nunez, Jill ^a   Chen, Lihren ^a   McKew, John C ^a   Mansour, Tarek S ^a   Xu, Xin ^a   Suri, Vipin ^a   Tam, May ^a   Xing, Yuzhe ^a   Li, Xiangping ^a   Hahm, Seung ^a   Tobin, James ^a   Saiah, Eddine ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; CORTISONE; HYDROCORTISONE; INSULIN; PIPERAZINE SULFONAMIDE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; HYPERINSULINEMIA; IC 50; IN VIVO STUDY; INSULIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CORTISONE; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HYPERINSULINISM; PIPERAZINES; RATS; SULFONAMIDES;

EID: 47749122576     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8004948     Document Type: Article

References (19)

1. Gerstein, H. C.; Yusuf, S. Dysglycaemia and risk of cardiovascular disease. Lancet 1996, 347, 949-950.
2. (a) Tomlinson, J. W.; Walker, E. A.; Bujalska, I. J.; Draper, N.; Lavery, G. G.; Cooper, M. S.; Hewison, M.; Stewart, P. M. 11β-Hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr. Rev. 2004, 25, 831-866.
3. (b) Stulnig, T. M.; Waldhausl, W. 11β-Hydroxysteroid dehydrogenase type 1 in obesity and type 2 diabetes. Diabetologia 2004, 47, 1-11.
4. (a) Masuzaki, H.; Paterson, J.; Shinyama, H.; Morton, N. M.; Mullins, J. J.; Seckl, J. R.; Flier, J. S. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001, 294, 2166-2170.
5. (b) Paterson, J. M.; Morton, N. M.; Fievet, C.; Kenyon, C. J.; Holmes, M. C.; Staels, B.; Seckl, J. R.; Mullins, J. J. Metabolic syndrome without obesity: hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 7088-7093.
6. (c) Morton, N. M.; Paterson, M.; Masuzaki, H.; Holmes, M.; Staels, B.; Fievet, C.; Walker, B.; Flier, J. S.; Mullins, J. J.; Seckl, J. R. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type-1 deficient mice. Diabetes 2004, 53, 931-938.
7. Barf, T.; Vallgarda, J.; Emond, R.; Haggstrom, C.; Kurz, G.; Nygren, A.; Larwood, V.; Mosialou, E.; Axelsson, K.; Olsson, R.; Engblom, L.; Edling, N.; Ronquist-Nii, Y.; Ohman, B.; Alberts, P.; Abrahmsen, L. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1. J. Med. Chem. 2002, 45, 3813-3815.
8. Alberts, P.; Nilsson, C.; Selen, G.; Engblom, L. O.; Edling, N. H.; Norling, S.; Klingstrom, G.; Larsson, C.; Forsgren, M.; Ashkzari, M.; Nilsson, C. E.; Fiedler, M.; Bergqvist, E.; Ohman, B.; Jorkstrand, E.; Abrahmsen, L. B. Selection inhibition of 11β-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 2003, 144, 4755-4762.
9. Walker, B. R.; Connacher, A. A.; Lindsay, M.; Webb, D. J.; Edwards, C. R. W. Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J. Clin. Endocrinol. Metab. 1995, 80, 3155-3159.
10. Kotelevtsev, Y. V.; Brown, R. W.; Fleming, S.; Kenyon, C.; Edwards, C. R. W.; Seckl, J. R.; Mullins, J. Hypertension in mice lacking 11β- hydroxysteroid dehydrogenase type 2. J. Clin. Invest. 1999, 103, 683-689.
11. (a) Saiah, E. The role of 11beta-hydroxysteroid dehydrogenase in metabolic disease and therapeutic potential of 11beta-HSD1 inhibitors. Curr. Med. Chem. 2008, 15 (7), 642-649.
12. (b) St. Jean, D. J.; Yuan, C.; Bercot, E. A.; Cupples, R.; Chen, M.; Fretland, J.; Hale, C.; Hungate, R. W.; Komorowski, R.; Veniant, M.; Wang, M.; Zhang, X.; Fotsch, C. 2-(S)-Phenethylaminothiazolones as potent, orally efficacious inhibitors of 11b-hydroxysteroid dehydrogenase type 1. J. Med. Chem. 2007, 50, 429-432.
13. (c) Xiang, J.; Ipek, M.; Suri, V.; Tam, M.; Xing, Y.; Huang, N.; Zhang, Y.; Tobin, J.; Mansour, T.; McKew, J. β-Keto sulfones as inhibitors of 11β- hydroxysteroid dehydrogenase type 1 and the mechanism of action. Bioorg. Med. Chem. 2007, 15, 4396-4405.
14. (d) Sorensen, B.; Winn, M.; Rohde, J.; Shuai, Q.; Wang, J.; Fung, S.; Monzon, K.; Chiou, W.; Stolarik, D.; Imade, H.; Pan, L.; Deng, X.; Chovan, L.; Longenecker, K.; Judge, R.; Qin, W.; Brune, M.; Camp, H.; Frevert, E. U.; Jackbson, P.; Link, J. T. Adamantane sulfone and sulfonamide 11-β-HSD1 inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 527-532.
15. (e) Yeh, V.; Kurukulasuriya, R.; Madar, D.; Patel, J.; Fung, S.; Monzon, K.; Chiou, W.; Wang, J.; Jacobson, P.; Sham, H.; Link, J. Synthesis and structural activity relationship of 11β-HSD1 inhibitors with novel adamantine replacements. Bioorg. Med. Chem. Lett. 2006, 16, 5408-5413.
16. (f) Schuster, D.; Maurer, E.; Laggner, C.; Nashev, L.; Wilckens, T.; Langer, T.; Odermatt, A. The discovery of new 11β- hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening. J. Med. Chem. 2006, 49, 3454-3466.
17. (g) Gu, X.; Dragovic, J.; Koo, G. C.; Koprak, S. L.; LeGrand, C.; Mundt, S. S.; Shah, K.; Springer, M.; Tan, E.; Thieringer, R.; Hermanowski-Vosatka, A.; Zokian, H.; Balkovec, J.; Waddell, S. T. Discovery of 4-heteroarylbicyclo[2.2. 2]octyltriazoles as potent and selective inhibitors of 11β-HSD1: novel therapeutic agents for the treatment of metabolic syndrome. Bioorg. Med. Chem. Lett. 2005, 15, 5266-5269.
18. (h) Olson, S.; Aster, S.; Brown, K.; Carbin, L.; Graham, D.; Hermanowski, A.; LeGrand, C.; Mundt, S.; Robbins, M.; Schaeffer, J.; Slossberg, L.; Szymonifka, M.; Thieringer, R.; Wright, S.; Balkovec, J. Adamantyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1. Bioorg. Med. Chem. Lett. 2005, 15, 4359-4362.
19. Xiang, J.; Saiah, E.; Tam, S.; McKew, J.; Chen, L.; Ipek, M.; Lee, K.; Li, H. ; Li, J. ; Li, W.; Mansour, T.; Suri, V.; Vargas, R.; Wu, Y.; Wan, Z.; Lee, J.; Binnun, E.; Wilson, D. 11-Beta HSD1 Inhibitors. WO 092435, 2007.